Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled, phase II study assessing the efficacy and
safety of Almonertinib compared Erlotinib or platinum doublet chemotherapy (carboplatin or
cisplatin + pemetrexed) as neoadjuvant therapy to EGFRm+ IIIA-N2 NSCLC patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University